Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Robitussin To Go spoons

This article was originally published in The Tan Sheet

Executive Summary

Wyeth Consumer Healthcare promotes pre-filled spoons of Robitussin Cough & Chest Congestion DM (dextromethorphan/guaifenesin) and Cough & Cold CF (dextromethorphan/guaifenesin/phenylephrine) for adult convenience. The two Robitussin To Go products are available nationwide at a suggested retail price of $8.69 for 10-count packs, a spokeswoman said in an e-mail. The products are indicated for consumers 12 years and older. Wyeth markets the products to consumers who "want a portable form for added convenience when they're on the go or away from home," the spokeswoman added. Robitussin To Go uses the RiteDose delivery system from The Ritedose Corp., which provides a similar device for McNeil Consumer Healthcare's pediatric allergy products Zyrtec Perfect Measure (cetirizine) and Benadryl Perfect Measure (diphenhydramine) (1"The Tan Sheet" Oct. 19, 2009)

You may also be interested in...



Dosing Device Paradigm Shifts For Liquid OTCs In Wake Of Safety Concerns

OTC drug manufacturers must consider a dosing device as a primary element of liquid product packaging to improve consumer safety through proper dosing, industry stakeholders say

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel